Clinical Trial Update: Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing safety and tolerability of patisiran (ALN-TTR02) in transthyretin amyloidosis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin-related Hereditary Amyloidosis
• Ttr-mediated Amyloidosis

Drugs mentioned

• Patisiran (patisiran)

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: TTR-mediated Amyloidosis | Phase 2 | Status: COMPLETED | Results posted: 2018-11-21